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ABSTRACT
Objectives: We previously found large variations in general practitioner (GP) hypertension treat-
ment probability in oldest-old (>80 years) between countries. We wanted to explore whether
differences in country-specific cardiovascular disease (CVD) burden and life expectancy could
explain the differences.
Design: This is a survey study using case-vignettes of oldest-old patients with different comor-
bidities and blood pressure levels. An ecological multilevel model analysis was performed.
Setting: GP respondents from European General Practice Research Network (EGPRN) countries,
Brazil and New Zeeland.
Subjects: This study included 2543 GPs from 29 countries.
Main outcome measures: GP treatment probability to start or not start antihypertensive treat-
ment based on responses to case-vignettes; either low (<50% started treatment) or high (50%
started treatment). CVD burden is defined as ratio of disability-adjusted life years (DALYs) lost
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due to ischemic heart disease and/or stroke and total DALYs lost per country; life expectancy at
age 60 and prevalence of oldest-old per country.
Results: Of 1947 GPs (76%) responding to all vignettes, 787 (40%) scored high treatment prob-
ability and 1160 (60%) scored low. GPs in high CVD burden countries had higher odds of treat-
ment probability (OR 3.70; 95% confidence interval (CI) 3.00–4.57); in countries with low life
expectancy at 60, CVD was associated with high treatment probability (OR 2.18, 95% CI
1.12–4.25); but not in countries with high life expectancy (OR 1.06, 95% CI 0.56–1.98).
Conclusions: GPs’ choice to treat/not treat hypertension in oldest-old was explained by differen-
ces in country-specific health characteristics. GPs in countries with high CVD burden and low life
expectancy at age 60 were most likely to treat hypertension in oldest-old.
KEY POINTS
 General practitioners (GPs) are in a clinical dilemma when deciding whether (or not) to treat
hypertension in the oldest-old (>80 years of age).
 In this study including 1947 GPs from 29 countries, we found that a high country-specific
cardiovascular disease (CVD) burden (i.e. myocardial infarction and/or stroke) was associated
with a higher GP treatment probability in patients aged >80 years.
 However, the association was modified by country-specific life expectancy at age 60. While
there was a positive association for GPs in countries with a low life expectancy at age 60,
there was no association in countries with a high life expectancy at age 60.
 These findings help explaining some of the large variation seen in the decision as to whether
or not to treat hypertension in the oldest-old.
Introduction
In the Global Burden of Disease (GBD) study (2015),
elevated blood pressure was among the leading risk
factors for disability-adjusted life years (DALYs) [1].
Globally, about 10% of all DALYs are lost due to
hypertension. To improve management of hyperten-
sion, the Lancet Commission issued a 10-point action
plan in which one of these points was to individualize
antihypertensive treatment according to cardiovascular
risk, cultural differences, age, etc. [2].
The group of the oldest-old (patients aged >80
years) is both the fastest growing and also the most
heterogeneous age group [3]. Some are healthy with
very few chronic conditions, whereas others are frail,
have multimorbidity (2 chronic conditions), or other
complex problems [4]. This heterogeneity makes it par-
ticularly challenging for general practitioners (GPs) to
find the best strategy (with optimal benefit to risk
ratio) when deciding whether or not elevated blood
pressure should be treated in this group [5]. This clin-
ical dilemma can lead to variation in treating hyper-
tension in oldest-old [6–9].
In the ATTENTIVE study [10], a large variation was
found in GPs’ decision to start antihypertensive treat-
ment in oldest-old. In that study, eight case vignettes
of oldest-old were presented to >2500 GPs from 29
(mainly) European countries and, for each case, they
were asked whether or not they would start treatment.
In the Netherlands, 34% of all cases would have been
treated compared with 88% in Ukraine. Part of
this variation was explained by the differences in
patient characteristics, i.e. level of blood pressure,
cardiovascular disease (CVD) and frailty. However,
given the variation across countries, it seems feasible
that country-specific health characteristics could
explain part of the variation.
Therefore, the present study investigates whether
country-specific health differences in CVD burden in
older patients, and life expectancy at age 60 years, are
related to GP treatment probability to start antihyper-
tensive treatment. We hypothesized that there would
be a positive association between CVD burden and GP
treatment probability, but that life expectancy at age
60 years would modify that association.
Materials and methods
Design and setting
This was an ecological study using a multilevel model.
Aggregated country-specific data were used from
publicly available sources (see section ‘Variables’) and
individual-level data (level of GPs) were used from
the Antihypertensive TreaTmENT In Very Elderly
(ATTENTIVE) study. In the ATTENTIVE study, GPs from
29 countries (including Brazil, Israel and New Zealand)
were enrolled (March–July 2016) [10].
Ethical considerations
The ATTENTIVE study was conducted in compliance
with the Declaration of Helsinki [11]. GPs provided
informed consent by responding to the questionnaire.
Since the participating GPs responded anonymously,
no formal medical ethics approval was required from
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most of the countries. However, in Brazil and
Switzerland, the research ethics committees issued a
waiver, and in New Zealand the research ethics com-
mittee of the University of Auckland approved this
study.
Participants
The only inclusion criterion for ATTENTIVE was that
each participant had to be a practicing GP; this was
established from the first question in the survey. Non-
practicing GPs were excluded. GPs were invited by
email without offering an incentive. For this study,
only GPs that provided an answer for all eight case
vignettes were included; this stipulation enabled us to
calculate GP treatment probability over all the cases.
Survey
In short, the survey contained eight case vignettes of
oldest-old patients (aged >80 years; males and
females) that consulted their GPs for a routine visit
without showing blood pressure-related symptoms or
receiving antihypertensive treatment. All case vignettes
differed in three primary characteristics: systolic blood
pressure (SBP) of 140 or 160mm Hg, CVD present or
absent, and frailty (yes or no). For each case vignette,
GPs were asked to decide if they would start antihy-
pertensive treatment. We piloted and then translated
the questionnaire into 21 languages (Additional file 1
in [10]). SurveyMonkey (www.surveymonkey.com, Palo
Alto, CA) was used to build the online questionnaire.
As an exception, in Ukraine (where web access was
limited) a paper questionnaire was used.
Variables
The outcome of this study was the proportion of case
vignettes for which GPs decided to start antihyperten-
sive treatment, i.e. GP treatment probability. GPs were
dichotomised into two groups according to the
median of GP treatment probability, i.e. 50% ‘low’,
>50% ‘high’.
The exposure was CVD burden per country. CVD
burden per country was defined as: the ratio of DALYs
in persons aged >70 years lost due to ischemic heart
disease and/or stroke and the total DALYs lost in per-
sons aged >70 years. These data were retrieved from
the GBD database (hosted by the Institute for Health
Metrics and Evaluation). Data specific for individuals
>80 years were not available why we chose the next
best estimate (>70). The GBD is a public database cap-
turing national estimates on total and disease-specific
DALYs [12]. The country-specific CVD burden ranged
from 16% in France to 59% in Ukraine (Appendix 1).
The countries were divided into two groups according
to the median of CVD burden, i.e. <22.5% (‘low’) and
22.5% (‘high’).
Country-specific life expectancy at age 60 years was
considered a possible effect modifier, and the preva-
lence of persons aged 80 years per country was con-
sidered a possible confounder for the association
between CVD burden and GP treatment probability.
Life expectancy at age 60 years was obtained from the
2015 Global Health Observatory data repository of the
World Health Organisation [13]. Prevalence of oldest-
old was available from the 2015 report of the United
Nations [14]. Data specific for individuals >80 years
were not available why we chose the next best esti-
mate (>60). Both covariates were dichotomized in two
quantiles according to their medians: life expectancy
at age 60 years, low (<24 years) and high (24 years)
and prevalence of oldest-old, low (<4.6%) and high
(4.6%).
Per GP, we included gender and years of experience
on an individual level from the ATTENTIVE data. Years
of experience was categorized into two groups of
about equal sizes: <15 years (‘low’) and 15 years
(‘high’).
The previous ATTENTIVE study [10] showed that
patient characteristics (SBP, CVD and frailty) were inde-
pendently associated with the GPs’ decisions to start
antihypertensive treatment. However, for the present
study, we were only interested in the overall effect of
CVD burden on GP treatment probability; therefore, as
an outcome, we chose the proportion of all case
vignettes for which GPs decided to start treatment,
and neglected the case characteristics (SBP, CVD and
frailty).
Statistical analysis
The ATTENTIVE dataset was visually explored and
checked for missing data, outliers and inconsistencies.
New dichotomized variables were generated (after
visual checks) by grouping of the distributions using
histograms. The exposure and all covariates were
checked for multicollinearity by calculating pairwise
correlation coefficients.
Chi-squared tests and unadjusted odds ratios (OR),
as well as 95% confidence intervals (CI), were used to
investigate whether the exposure (CVD burden) and
the other independent variables (GP gender/years of
experience, life expectancy at age 60, and prevalence
of oldest-old) were associated with the outcome (GP
treatment probability).
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On a country level, continuous data of CVD burden
and averaged GP treatment probability per country
were visualized using scatter plots. A linear regression
line with 95% CI was derived using a univariate linear
regression model. In a sensitivity analysis, this analysis
was restricted to those countries where >60% of the
GPs responded to the survey.
Chi-squared tests were then used to investigate
whether CVD burden was associated with any of the
independent variables and, if not on a causal pathway,
these were considered to be potential confounders.
All potential confounders were tested for the
degree of confounding and/or effect modification
using the Mantel–Haenszel test of homogeneity of ORs
(detailed in Appendix 3). As pre-specified, the causal
model presented stratum-specific ORs and 95% CI for
low and high life expectancy at age 60 years. Variables
that confounded the association between the expos-
ure and the outcome were included in the final
model.
A two-sided p value of .05 was considered statistic-
ally significant. All analyses were performed in STATA
release 14.2 (Stata Corp, College Station, TX).
Results
In the ATTENTIVE study, 2543 GPs from 29 countries
participated. The median response rate for all coun-
tries was 26% (21 countries with <60%, eight coun-
tries with 60%). Of those participating, 1947 GPs
(76.6%), provided an answer for all eight case
vignettes.
Table 1 presents the baseline characteristics of the
participating GPs and the countries, stratified by GP
treatment probability. There were 1160 (59.6%) GPs
with a low and 787 (40.4%) GPs with a high GP treat-
ment probability. Countries with a high CVD burden
showed a positive association with GP treatment prob-
ability (OR 3.70, 95% CI 3.03, 4.52; p < .001).
Figure 1 shows the association between CVD bur-
den and GP treatment probability on a country level
using continuous data. Strong evidence was found for
an association between CVD burden and GP treatment
probability (p < .001). Of all countries, the Netherlands
had the lowest GP treatment probability (34%) and
one of the lowest CVD burdens (16%), whereas
Ukraine was among the countries with both the high-
est GP treatment probability (88%) and CVD burden
(59%). When restricting the analysis to countries with
a response rate of >60%, the sensitivity analysis con-
firmed this association (p = .001) (Appendix 2).
In countries with a high CVD burden, the ORs for
treatment were higher compared to countries with a
low CVD burden (3.70, 95% CI 3.00, 4.57). Country-spe-
cific prevalence of oldest-old was a significant con-
founder (adjusted OR 2.71, 95% CI 2.17, 3.38) while GP
gender and GP years of experience were not con-
founders. Life-expectancy at age 60 years was an effect
modifier (the Mantel–Haenszel test of homogeneity
p = .005) of the association between CVD burden and
GP treatment probability. Therefore, we included coun-
try-specific prevalence of oldest-old in the multivariate
model and present stratum specific estimates for low
and high life expectancy at age 60 years.
In the final model (Table 2), GPs working in coun-
tries with a high CVD burden and a low life expect-
ancy at age 60 years were more likely to start
antihypertensive treatment in the oldest-old (adjusted
OR 2.18, 95% CI 1.12, 4.25) compared to their counter-
parts in countries with a low CVD burden. In countries
Table 1. Baseline characteristics of general practitioners (GPs) and countries, and their association with
high GP treatment probability to start antihypertensive treatment in oldest-old (n¼ 1947).
GP treatment probability
Characteristics
Low (50%)
(n¼ 1160)
High (>50%)
(n¼ 787)
Crude odds ratio of high
GP treatment probability (95% CI) p Value
GP gender
Female 535 (54.6) 445 (45.4) 1.00 (reference)
Male 625 (64.6) 342 (35.4) 0.66 (0.55, 0.79) <.001
Experience as GP
<15 years 558 (56.7) 427 (43.4) 1.00 (reference)
>15 years 602 (62.7) 358 (37.3) 0.78 (0.65, 0.93) .007
Prevalence of oldest-old
Low 404 (45.0) 493 (55.0) 1.00 (reference)
High 756 (72.0) 294 (28.0) 0.32 (0.26, 0.38) <.001
Life expectancy at age 60 years
Low 216 (36.4) 378 (63.6) 1.00 (reference)
High 944 (69.8) 409 (30.2) 0.25 (0.20, 0.30) <.001
Cardiovascular disease burden
Low 930 (69.4) 411 (30.7) 1.00 (reference)
High 230 (38.0) 376 (62.1) 3.70 (3.03, 4.52) <.001
p Values are from univariate logistic regression.
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with a high life expectancy at age 60 years, there was
no evidence for such an association (adjusted OR 1.06,
95% CI 0.56, 1.98).
Discussion
Statement of principle findings
The clinical dilemma when deciding whether (or not)
to start antihypertensive treatment in the oldest-old
may not only be explained by differences in patient
characteristics but also in country-specific characteris-
tics. In the present study including 1947 GPs from 29
countries, a high country-specific CVD burden was
associated with a higher probability of GPs deciding to
start antihypertensive treatment in patients aged >80
years. However, the association was modified by coun-
try-specific life expectancy at age 60 years. While there
was a positive association for GPs in countries with a
low life expectancy at age 60 years, there was no asso-
ciation for GPs in countries with a high life expectancy
at age 60 years. These findings (partly) explain some
of the large variation seen in the decision as
to whether or not to treat hypertension in the oldest-
old [10].
Strengths and limitations
The inclusion of a large number of GPs from a large
number of countries (in Europe and beyond) is a
strength of this study; this allowed us to study the
relation between country-specific health characteristics
and GP decisions in an ecological analysis. Also, we
could describe GP treatment probabilities in countries
that are not usually included in international studies.
This study also has limitations. First, GP treatment
probability was self-reported and based on fictive
cases stories and not on, for example, chart reviews.
Second, the overall response rate was only 26% across
all countries, which is not uncommon in surveys
involving GPs [15]. However, our response rate was
not lower than in other GP survey studies [16,17] and
low response rates of GPs do not necessarily result in
selection bias [18,19]. In addition, when restricting our
analysis to countries where the GPs responded for
60%, the results remained unchanged. Third, we can
only report associations and not causation as this was
an observational study with limitations such as
residual confounding. However, we explored and
reported patient-related factors associated with GP
treatment probability in an earlier study [10].
Figure 1. Association between country-specific cardiovascular disease burden and mean general practitioner (GP) treatment prob-
ability per country in oldest-old. Univariate linear regression was used (straight line), 95% confidence intervals (outer lines) and p
value. FR: France; NZ: New Zealand; SE: Sweden; UK: United Kingdom.
Table 2. Final model including 1947 GPs for the association
of cardiovascular disease (CVD) burden on GP treatment prob-
ability in oldest-old.
Fully-adjusted odds ratio of
GP treatment probability
(95% CI)
CVD burden (stratum-specific)
Low life expectancy at age 60 2.18 (1.12, 4.25)
High life expectancy at age 60 1.06 (0.56, 1.98)
Prevalence of oldest-old 0.48 (0.39, 0.59)
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Findings in relation to other studies
The results from this study suggest that GPs in coun-
tries where their 60-year-old patients will die (on aver-
age) before the age of 84 years, base their decision to
start antihypertensive treatment in the oldest-old not
only on the individual risk or prevalence of oldest-old,
but also on the CVD burden of their country. In our
opinion, the daily experience and case load provide
GPs with sufficient knowledge to assess CVD burden
and country-specific DALY of the patients that they see
and treat, even without knowing the exact burden.
DALYs due to CVD burden are not only a problem in
high-income countries but mostly in low- and middle-
income countries (LMIC) [20]. The inequity in cardiovas-
cular health in LMIC compared to high-income countries,
calls for empowering GPs with the knowledge/skills to
meet the requirements in these countries [21]. While
our study shows that, in countries with a lower life-
expectancy, GPs are more inclined to treat hypertension
when CVD burden is high, the effects of such treatment
on e.g. mortality or patient-relevant outcomes such as
quality of life, remain unclear. Treatment goals for
hypertension (especially in older patients) are con-
stantly changing [22]. Although trials including oldest-
old show a clear benefit of lowering blood pressure
[23,24], the generalizability of these studies is still
debated [22,25–27]. In this clinical dilemma, prognosis
and life expectancy are issues that GPs relate to in the
decision-making process in older patients [6].
Meaning of the study
Future high-quality observational studies, or new trials
including the otherwise excluded frail patients with
multimorbidity, should be conducted to provide more
evidence for decision-making with respect to hyper-
tension treatment in the oldest-old. With evidence
that can be generalized for GP patients that are frail
and multimorbid, the implementation into daily prac-
tice should be thoughtfully planned. Our study found
also a crude association of female GPs and GPs with a
shorter than 15-year experience to treat more often
hypertension in oldest-old. Future studies could further
investigate if this association is real. These steps are
needed to overcome inequities in treatment decisions
across countries with different CVD burdens and life
expectancies.
Conclusions
The clinical dilemma when deciding whether (or not)
to start antihypertensive treatment in the oldest-old
appears not only to be explained by differences in
patient characteristics but also in country-specific
health characteristics. In this ecological comparative
study, GPs living in countries with a high CVD burden
and low life expectancy at age 60 years were more
likely to start antihypertensive treatment in the oldest-
old than GPs in countries with a low CVD burden and
a high life expectancy at age 60 years.
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Appendix 1
Characteristics of all 29 included countries (number of GPs included per country)
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Appendix 2
Sensitivity analysis including only countries with a response rate of >60% (n = 8). Association between countryspecific cardio-
vascular disease (CVD) burden on mean general practitioner (GP) treatment probability per country in oldestold. Univariate lin-
ear regression was used (red line), 95% confidence intervals (grey lines) and p-value. UK = United Kingdom
Appendix 3
Assessing confounding and testing for effect modification on the association of cardiovascular disease (CVD) burden on GP
treatment probability in oldest-old.
Odds ratio of GP treatment probability (95% CI) P-value
Unadjusted effect of CVD burden 3.70 (3.00, 4.57)
Effect of CVD burden adjusted for …
Gender 3.55 (2.87, 4.41) 0.19
Female 4.01 (3.01, 5.34)
Male 3.01 (2.18, 4.16)
High experience (15 years) 3.73 (3.02, 4.60) 0.87
Low 3.79 (2.81, 5.12)
High 3.66 (2.71, 4.93)
Life expectancy at age 60 1.48 (0.97, 2.29) 0.005
Low 2.96 (1.53, 5.72)
High 0.82 (0.44, 1.53)
Prevalence of oldest old 2.71 (2.17, 3.38) 0.57
Low 2.59 (1.96, 3.41)
High 2.96 (2.06, 4.24)
P-values are from Mantel-Haenszel test of homogeneity of odds ratios. Variables in grey were chosen for the final model.
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